CN1149215C - 苯基黄嘌呤衍生物 - Google Patents

苯基黄嘌呤衍生物 Download PDF

Info

Publication number
CN1149215C
CN1149215C CNB998119695A CN99811969A CN1149215C CN 1149215 C CN1149215 C CN 1149215C CN B998119695 A CNB998119695 A CN B998119695A CN 99811969 A CN99811969 A CN 99811969A CN 1149215 C CN1149215 C CN 1149215C
Authority
CN
China
Prior art keywords
tetrahydro
purin
dioxo
bis
methyl ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998119695A
Other languages
English (en)
Chinese (zh)
Other versions
CN1323309A (zh
Inventor
S��M����³��
S·M·达鲁格
�ڶ�ɭ
C·H·于尔根森
M·T·马丁
�غ�����
M·H·奥斯特豪特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1323309A publication Critical patent/CN1323309A/zh
Application granted granted Critical
Publication of CN1149215C publication Critical patent/CN1149215C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998119695A 1998-08-13 1999-08-11 苯基黄嘌呤衍生物 Expired - Fee Related CN1149215C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9817623.3 1998-08-13
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB031104673A Division CN1251676C (zh) 1998-08-13 1999-08-11 苯基黄嘌呤衍生物

Publications (2)

Publication Number Publication Date
CN1323309A CN1323309A (zh) 2001-11-21
CN1149215C true CN1149215C (zh) 2004-05-12

Family

ID=10837179

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998119695A Expired - Fee Related CN1149215C (zh) 1998-08-13 1999-08-11 苯基黄嘌呤衍生物
CNB031104673A Expired - Fee Related CN1251676C (zh) 1998-08-13 1999-08-11 苯基黄嘌呤衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB031104673A Expired - Fee Related CN1251676C (zh) 1998-08-13 1999-08-11 苯基黄嘌呤衍生物

Country Status (36)

Country Link
US (3) US6608069B1 (enExample)
EP (1) EP1104422B1 (enExample)
JP (3) JP3631961B2 (enExample)
KR (1) KR20010085369A (enExample)
CN (2) CN1149215C (enExample)
AP (1) AP1408A (enExample)
AR (1) AR020154A1 (enExample)
AT (1) ATE259810T1 (enExample)
AU (1) AU775819B2 (enExample)
BR (1) BR9913020A (enExample)
CA (1) CA2340350A1 (enExample)
CO (1) CO5130007A1 (enExample)
DE (1) DE69914921T2 (enExample)
DK (1) DK1104422T3 (enExample)
EA (1) EA004139B1 (enExample)
EE (1) EE04721B1 (enExample)
ES (1) ES2215399T3 (enExample)
GB (1) GB9817623D0 (enExample)
HU (1) HUP0103637A3 (enExample)
ID (1) ID28723A (enExample)
IL (1) IL141318A0 (enExample)
IS (1) IS5843A (enExample)
MA (1) MA26673A1 (enExample)
MY (1) MY133393A (enExample)
NO (1) NO20010715L (enExample)
NZ (1) NZ509778A (enExample)
PE (1) PE20000952A1 (enExample)
PL (1) PL346055A1 (enExample)
PT (1) PT1104422E (enExample)
SI (1) SI1104422T1 (enExample)
SK (1) SK2222001A3 (enExample)
TR (1) TR200100448T2 (enExample)
TW (1) TWI224598B (enExample)
WO (1) WO2000009507A1 (enExample)
YU (1) YU11601A (enExample)
ZA (1) ZA200101186B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002067942A2 (en) * 2001-02-28 2002-09-06 Smithkline Beecham Corporation Methods of treating irritable bowel syndrome and functional dyspepsia
EP1418882A1 (en) 2001-08-24 2004-05-19 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994128B1 (en) * 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
IL320958A (en) 2022-12-20 2025-07-01 Invios Gmbh 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES TRANSFORMERS AND THEIR USES
EP4389749A1 (en) * 2022-12-20 2024-06-26 invIOs GmbH Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (enExample) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
SI0812844T1 (en) 1996-06-07 2003-02-28 Hoechst Aktiengesellschaft Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
EP1104422B1 (en) 2004-02-18
JP2004137251A (ja) 2004-05-13
US6770267B2 (en) 2004-08-03
MY133393A (en) 2007-11-30
YU11601A (sh) 2004-03-12
ID28723A (id) 2001-06-28
CA2340350A1 (en) 2000-02-24
PL346055A1 (en) 2002-01-14
PE20000952A1 (es) 2000-09-29
CN1251676C (zh) 2006-04-19
CO5130007A1 (es) 2002-02-27
DE69914921D1 (en) 2004-03-25
US6608069B1 (en) 2003-08-19
TR200100448T2 (tr) 2001-09-21
CN1323309A (zh) 2001-11-21
JP3631961B2 (ja) 2005-03-23
ES2215399T3 (es) 2004-10-01
KR20010085369A (ko) 2001-09-07
ZA200101186B (en) 2002-02-12
US20040034020A1 (en) 2004-02-19
AR020154A1 (es) 2002-04-10
TWI224598B (en) 2004-12-01
SK2222001A3 (en) 2001-12-03
AU775819B2 (en) 2004-08-19
US20030032804A1 (en) 2003-02-13
ATE259810T1 (de) 2004-03-15
EA004139B1 (ru) 2004-02-26
BR9913020A (pt) 2001-05-08
CN1515571A (zh) 2004-07-28
MA26673A1 (fr) 2004-12-20
SI1104422T1 (en) 2004-06-30
DE69914921T2 (de) 2004-12-23
WO2000009507A1 (en) 2000-02-24
AP2001002071A0 (en) 2001-03-31
GB9817623D0 (en) 1998-10-07
EP1104422A1 (en) 2001-06-06
AU5732399A (en) 2000-03-06
EE04721B1 (et) 2006-10-16
EE200100083A (et) 2002-06-17
HUP0103637A2 (en) 2002-06-29
IS5843A (is) 2001-02-09
DK1104422T3 (da) 2004-06-14
NO20010715D0 (no) 2001-02-12
NZ509778A (en) 2003-08-29
NO20010715L (no) 2001-04-02
AP1408A (en) 2005-05-06
IL141318A0 (en) 2002-03-10
JP2002522542A (ja) 2002-07-23
HK1035195A1 (en) 2001-11-16
JP2004115534A (ja) 2004-04-15
HUP0103637A3 (en) 2002-10-28
EA200100127A1 (ru) 2001-10-22
PT1104422E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
CN1251676C (zh) 苯基黄嘌呤衍生物
CN1042730C (zh) 吡唑并吡啶化合物的制备方法
CN1043348C (zh) 不对称取代的黄嘌呤、其制备方法及其作为药物组合物的应用
CN1021328C (zh) 新的哒嗪胺衍生物的制备方法
CN1659148A (zh) 芳基肟化合物
CN1144791C (zh) 三唑化合物及其作为多巴胺d3配体的应用
CN1400975A (zh) 嘌呤衍生物
CN1816549A (zh) 磷脂酰肌醇3－激酶抑制剂
CN1460105A (zh) 黄嘌呤磷酸二酯酶v抑制剂
CN1585769A (zh) A2b腺苷受体拮抗剂
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
CN1547583A (zh) 多环鸟嘌呤磷酸二酯酶v抑制剂
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1856496A (zh) 抑制hiv复制的嘌呤衍生物
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1125445A (zh) 具有p.de-iv抑制活性的新型化合物
CN1608067A (zh) 作为磷酸二酯酶vii抑制剂的吡咯并嘧啶化合物
CN1894250A (zh) 取代的8－杂芳基黄嘌呤
CN1422273A (zh) 1,5－二取代－3,4－二氢－1H－嘧啶并[4,5－d]嘧啶二酮化合物和其在治疗CSBP/p38激酶介导的疾病中的用途
CN101056634A (zh) 奎宁环衍生物及它们作为毒蕈碱m3受体拮抗剂的用途
CN1890241A (zh) A2b腺苷受体拮抗剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1238771A (zh) 用作α－2肾上腺素能受体兴奋剂的2－咪唑啉基氨基吲哚化合物
CN1140527C (zh) 苯基黄嘌呤酯和酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee